Post Profile

Vertex picks cystic fibrosis triple combos for Phase III trials

(Reuters) - Vertex Pharmaceuticals said on Wednesday it selected two next-generation cystic fibrosis drugs to advance into late-stage testing of triple-combination therapies that could eventually treat up to 90 percent of patients with the life-shortening lung disease.
read more


Related Posts

Novel Drug Combo Improves Function of Cystic Fibrosis Protein

Health : Newswise Medical News

A novel two-drug combination has the potential to target and restore a defective protein underlying cystic fibrosis (CF), according to two phase III clinical trials conducted at 187 medical centers around the world, including Johns ...

Phase 2 Study Of Two Potential CF Therapies - VX-770 And VX-809 - Shows Promising Results In Patients With Most Common Mutation

Health : Medical News Today

Vertex Pharmaceuticals Incorporated and the Cystic Fibrosis Foundation today announced promising results from an ongoing Phase 2 study evaluating combinations of VX-770 and VX-809, potential medicines designed to treat the defective...

Vertex Pharma shares hit life high as cystic fibrosis data wows

Health : Reuters: Health

(Reuters) - Shares of Vertex Pharmaceuticals Inc soared to touch a record high on Wednesday, a day after the drugmaker revealed data on its triple combinations of cystic fibrosis (CF) treatments that wowed both analysts and investor...

Vertex cystic fibrosis combination succeeds in late-stage trials

Health : Reuters: Health

(Reuters) - Vertex Pharmaceuticals Inc said on Tuesday its Kalydeco cystic fibrosis treatment given with an experimental drug demonstrated significant improvements in lung function in a pair of late-stage trials the company plans to...

Vertex reports positive results for cystic fibrosis triple combos

Health : Reuters: Health

(Reuters) - Vertex Pharmaceuticals Inc on Tuesday said three different triple combinations of cystic fibrosis treatments significantly improved patient lung function in clinical trials, bolstering its goal of a therapy that could he...


Copyright © 2016 Regator, LLC